/BLTE
BLTE Stock - Belite Bio, Inc
Healthcare|BiotechnologyNASDAQ
$156.00+0.94%
+$1.46 (+0.94%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).73
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.7%upside
Target: $174.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BLTE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$154.44 – $157.56
TARGET (TP)$174.20
STOP LOSS$143.52
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.45
52W High$162.00
52W Low$49.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-39,996,000 | $-31,668,000 | $-12,821,000 | $-9,797,000 | $-5,743,000 |
| Net Income | $-36,144,000 | $-31,632,000 | $-12,648,000 | $-9,666,000 | $-5,753,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.18 | $-1.19 | $-0.63 | $-0.40 | $-0.62 |
Company Overview
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$87
Average Target
↓ 44.2% Downside
Now
$25
Low
$87
Average
$194
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Mizuho | Upgrade | Outperform | $194 |
| November 24th 2025 | Cantor Fitzgerald | Resumed | Overweight | $154 |
| November 20th 2025 | Mizuho | Initiation | Neutral | $105 |
| December 14th 2023 | Maxim Group | Initiation | Buy | $60 |
| July 28th 2023 | Cantor Fitzgerald | Initiation | Overweight | $43 |
| July 26th 2023 | SVB Securities | Initiation | Outperform | $25 |
| August 1st 2022 | H.C. Wainwright | Initiation | Buy | $58 |
| July 1st 2022 | The Benchmark Company | Initiation | Buy | $57 |
Earnings History & Surprises
BLTEBeat Rate
31%
Last 13 quarters
Avg Surprise
-33.9%
EPS vs Estimate
Beats / Misses
4/9
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
+30.6%
$-0.25vs$-0.36
Q2 24
+20.6%
$-0.27vs$-0.34
Q3 24
-10.7%
$-0.31vs$-0.28
Q4 24
+6.7%
$-0.28vs$-0.30
Q1 25
-6.7%
$-0.32vs$-0.30
Q2 25
-25.0%
$-0.45vs$-0.36
Q3 25
-6.4%
$-0.50vs$-0.47
Q4 25
-22.6%
$-0.65vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-0.53 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.53 | $-0.65 | -22.6% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.47 | $-0.50 | -6.4% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.36 | $-0.45 | -25.0% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q1 2024 | Mar 11, 2024 | $-0.36 | $-0.25 | +30.6% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.31 | $-0.40 | -29.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.20 | $-0.33 | -65.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.22 | $-1.04 | -374.4% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-0.10 | — | — |
Q3 2022 | Aug 10, 2022 | $-0.23 | $-0.12 | +49.7% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | — | $-0.26 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.05 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.26 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.25 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.25 | — | — |
Latest News
Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194
📈 PositiveBenzinga•Dec 2, 2025, 03:06 PM
Reported Earlier, Belite Bio Prices $350M Underwritten Public Offering Of 2.27M American Depositary Shares At $154 Each To Advance Retinal Therapeutics
📈 PositiveBenzinga•Dec 2, 2025, 06:36 AM
Belite Bio Announces Proposed Underwritten Public Offering Of American Depositary Shares; No Terms Disclosed
➖ NeutralBenzinga•Dec 1, 2025, 09:20 PM
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $185
📈 PositiveBenzinga•Dec 1, 2025, 06:14 PM
Belite Bio shares are trading higher after the company reported Phase 3 DRAGON trial results showing tinlarebant reduced Stargardt disease lesion growth.
📈 PositiveBenzinga•Dec 1, 2025, 01:43 PM
Belite Bio Unveils Phase 3 DRAGON Trial Results Showing Tinlarebant Significantly Reduces Stargardt Disease Lesion Growth
📈 PositiveBenzinga•Dec 1, 2025, 11:02 AM
Belite Bio shares are trading higher. Cantor Fitzgerald assumed the stock at Overweight and announced a price target of $154.
📈 PositiveBenzinga•Nov 24, 2025, 07:13 PM
Cantor Fitzgerald Assumes Belite Bio at Overweight, Announces Price Target of $154
📈 PositiveBenzinga•Nov 24, 2025, 02:21 PM
Mizuho Initiates Coverage On Belite Bio with Neutral Rating, Announces Price Target of $105
➖ NeutralBenzinga•Nov 20, 2025, 04:11 PM
Belite Bio Q3 EPS $(0.65) Misses $(0.45) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 01:03 PM
Reported Sunday, Belite Bio Receives United Kingdom Medicines And Healthcare Products Regulatory Agency Agreement To Submit Conditional Marketing Authorization Application For Tinlarebant Following Positive Interim Results From Phase 3 DRAGON Trial
📈 PositiveBenzinga•Nov 3, 2025, 07:58 AM
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
📈 PositiveBenzinga•Oct 31, 2025, 02:08 PM
Belite Bio Says Center For Drug Evaluation Of China's NMPA Agrees To Accept NDA With Priority Review For Tinlarebant For Treatment Of Stargardt Disease Based On Interim Analysis Results From Phase 3 DRAGON Trial
📈 PositiveBenzinga•Oct 15, 2025, 12:12 PM
HC Wainwright & Co. Maintains Buy on Belite Bio, Lowers Price Target to $98
📈 PositiveBenzinga•Sep 15, 2025, 11:44 AM
Belite Bio Completes Last Subject Visit In Phase 3 DRAGON Clinical Trial Evaluating Tinlarebant For Treatment Of Stargardt Disease Type 1
➖ NeutralBenzinga•Sep 12, 2025, 12:07 PM
Belite Bio Announces $125M PIPE Financing At $64/Share With 1.95M Shares and Warrants; Potential Additional $150M At $76.80/Share
📈 PositiveBenzinga•Sep 8, 2025, 12:07 PM
Belite Bio gets FDA breakthrough therapy status for Stargardt disease treatment
📈 PositiveSeeking Alpha•May 21, 2025, 01:14 PM
Frequently Asked Questions about BLTE
What is BLTE's current stock price?
Belite Bio, Inc (BLTE) is currently trading at $156.00 per share. The stock has moved +0.94% today.
What is the analyst price target for BLTE?
The average analyst price target for BLTE is $174.20, based on 1 analyst.
What sector is Belite Bio, Inc in?
Belite Bio, Inc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BLTE's market cap?
Belite Bio, Inc has a market capitalization of $5.44 billion, making it a mid-cap company.
Does BLTE pay dividends?
No, Belite Bio, Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ADMA
ADMA Biologics, Inc.
$19.58
Mkt Cap: $4.7B
ARQT
Arcutis Biotherapeutics, Inc.
$28.01
Mkt Cap: $3.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to BLTE for comparison